Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05799274 · ClinicalTrials.gov registry record · Phase 1
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
A Phase 1 study of Ovarian Cancer and Healthy Volunteers, sponsored by Radiopharm Theranostics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 2
- Study locations
NCT05799274 is a Phase 1 study of Ovarian Cancer and Healthy Volunteers that is actively recruiting participants, run by Radiopharm Theranostics. The registered enrollment target is 9 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05799274, a Phase 1 study of Ovarian Cancer and Healthy Volunteers, is actively recruiting participants, sponsored by Radiopharm Theranostics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
Conditions Studied
Interventions
- DRUG RAD301 ([68Ga]-RAD301)
Study Locations (2)
New Jersey
- United Theranostics - Princeton
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2025-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05799274
The ClinicalTrials.gov registry entry for NCT05799274 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Radiopharm Theranostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which RAD301 ([68Ga]-RAD301) is the first listed.
NCT05799274 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT05799274 about?
NCT05799274 is a clinical study titled "Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors". This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
What is the current status of trial NCT05799274?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-11-09. Estimated completion is 2025-11.
What conditions does trial NCT05799274 study?
This clinical trial studies the following conditions: Ovarian Cancer, Healthy Volunteers, Endometrial Cancer, Cervical Cancer, Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT05799274?
The interventions under investigation include: RAD301 ([68Ga]-RAD301) (DRUG).
Who is sponsoring clinical trial NCT05799274?
This trial is sponsored by Radiopharm Theranostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05799274 being conducted?
This trial has 2 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.